Abstract: Neuropsychiatric disorders include bipolar disorder, schizophrenia, and major depression. They present significant challenges to clinical management due to their complex pathophysiology and diverse symptomatology. Despite advancements in psychopharmacology, existing treatments often exhibit partial efficacy, variable patient responses, and substantial side effect profiles, which underscores the need for novel therapeutic strategies. This review provides a comprehensive examination of recent breakthroughs in the design, expansion, and delivery of pharmacological mediators intended for improving the management of neuropsychiatric disorders. We explore cutting-edge drug-delivery systems, such as liposomes, nanoparticles, and polymeric micelles, which enhance drug bioavailability and targetability, thereby facilitating more effective crossing of the blood-brain barrier. The integration of nanotechnology-based approaches and ligand-targeted delivery systems has shown promise in optimizing therapeutic concentrations within the central nervous system while minimizing systemic toxicity. Advances in prodrug formulations and carrier-mediated transport mechanisms are discussed as innovative strategies to improve drug solubility, absorption, and sustained release. This review also underscores the potential of personalized medicine and biomarkerdriven approaches in customizing treatment regimens to individual patient profiles, thereby enhancing therapeutic efficacy and clinical outcomes. These innovations in drug design and delivery hold significant promise for revolutionizing the treatment landscape of neuropsychiatric disorders, offering hope for improved patient care and quality of life.
Mohapatra et al. (Tue,) studied this question.